scholarly journals In vitro single-strand DNA damage and cancer cell cytotoxicity effects of Temozolomide

Oncomedicine ◽  
2017 ◽  
Vol 2 ◽  
pp. 102-110 ◽  
Author(s):  
Shruti Purohit ◽  
Devashree Jahagirdar ◽  
Azad Kumar ◽  
Nilesh Kumar Sharma
Keyword(s):  
Dna Damage ◽  
Cancer Cell ◽  
Single Strand ◽  
Cell Cytotoxicity ◽  
Cytotoxicity Effects

scholarly journals Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo

2013 ◽  
Vol 134 (5) ◽  
pp. 1102-1111 ◽  
Author(s):  
Karen J. Bowman ◽  
Manar M. Al‐Moneef ◽  
Benedict T. Sherwood ◽  
Alexandra J. Colquhoun ◽  
Jonathan C. Goddard ◽  
...  
Keyword(s):  
Dna Damage ◽  
Bladder Cancer ◽  
Comet Assay ◽  
Cancer Cell ◽  
Bladder Cancer Cell ◽  
Treatment Sensitivity

scholarly journals In-vitro cancer cell cytotoxicity and alpha amylase inhibition effect of seven tropical fruit residues

2014 ◽  
Vol 4 ◽  
pp. S665-S671 ◽  
Author(s):  
Priti Gupta ◽  
Ira Bhatnagar ◽  
Se-Kwon Kim ◽  
Ajay Kumar Verma ◽  
Anubhuti Sharma
Keyword(s):  
Cancer Cell ◽  
Alpha Amylase ◽  
Cell Cytotoxicity ◽  
Tropical Fruit ◽  
Inhibition Effect

scholarly journals Cytotoxic, genotoxic and apoptotic effects of Viburnum opulus on colon cancer cells: an in vitro study

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Kubra Bozali ◽  
Eray Metin Guler ◽  
Ahmet Sadik Gulgec ◽  
Abdurrahim Kocyigit
Keyword(s):  
Colorectal Cancer ◽  
Dna Damage ◽  
Cell Viability ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Methanolic Extract ◽  
Cancer Cell Line ◽  
Dependent Manner ◽  
Apoptotic Effects

AbstractObjectiveIntake of various fruits is quite significant for maintaining the human body, due to their supply of useful constituents. V. opulus has been found to have outstanding antioxidant activity while showing a pro-oxidant effect at high doses. Due to this feature, V. opulus would be anticipated to have a healing impact on cancer treatment. In this study, it has been proposed to examine the cytotoxic, genotoxic, and apoptotic effects of V. opulus on human colorectal cancer cell.MethodDifferent concentrations of V. opulus methanolic extract (5–2000 μg/mL) were incubated for 24 h with colorectal cancer cell line (Lovo). The cell viability, intracellular reactive oxygen species (iROS), DNA damage, and apoptosis were measured after incubation.ResultsThe obtained results of this research demonstrate decreased cell viability and increased DNA damage, iROS, and apoptosis levels of V. opulus in Lovo cells in a concentration-dependent manner in the range of 14.88–52.06%. There were strong positive relationships between apoptosis, genotoxicity, and cytotoxicity in V. opulus methanolic extract treated cancer cell line.DiscussionThis in vitro research clearly demonstrated that V. opulus methanolic extract induces DNA damage, apoptosis, and cytotoxicity in a dose-dependent manner in cancer cells due to its pro-oxidant activity.ConclusionAlthough in vitro results are favorable, in vivo and further studies are needed.

Glypican-1 as a novel immunotherapeutic target in prostate cancer.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 174-174 ◽  
Author(s):  
Alexander Zaslavsky ◽  
Mackenzie Adams ◽  
Sandra Wissmueller ◽  
Douglas Campbell ◽  
Hans Klingemann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Flow Cytometry ◽  
Cell Lines ◽  
Cancer Cell ◽  
Prostate Cancer Cell ◽  
Cancer Cell Lines ◽  
Parental Line ◽  
Cell Cytotoxicity ◽  
Prostate Cancer Cell Lines

174 Background: New effective therapies for men with prostate cancer are desperately needed. Recently, cancer immunotherapy has emerged as an important new treatment strategy for prostate cancer and for castrate resistant prostate cancer (CRPC). Multiple studies have identified the heparan sulfate proteoglycan-1 Glypican 1 (GPC-1) as being overexpressed in different cancers, and also as being a possible marker of poor prognosis in several solid tumor cancers. GPC-1 has been recently identified as a potential marker for prostate cancer. The MIL-38 monoclonal antibody detects GPC-1 and an IgG1 chimeric version of this antibody has been developed for preclinical studies. Here we sought to examine MIL-38 binding to a panel of prostate cancer cell lines and examine its feasibility as a novel immunotherapeutic agent targeting GPC-1 in prostate cancer Methods: Expression of GPC-1 in CRPC cell lines was examined by Flow cytometry and Western Blotting using MIL-38 as the detector antibody. The competency of GPC-1 as an immunotherapeutic target was assessed via chimeric MIL-38 induced Antibody Dependent Cell Cytotoxicity (ADCC) using high affinity Natural Killer cells (haNKs) in vitro . Results: Flow cytometry and Western blot assessments of normal prostatic epithelial cells (i.e. RWPE-1) and cells from prostate cancer cell lines (i.e. PC-3, 22RV1, DU-145, VCaP, LNCaP, CWR-R1, and LAPC-4) revealed that only cancer cells expressed GPC-1. Enzalutamide resistant cell lines demonstrated higher expression of GPC-1 than their respective parental line. ADCC assays demonstrated enhanced haNK – prostate cancer cell cytotoxicity in the presence of chimeric MIL-38 anti-GPC-1 antibody, while the IgG1 isotype control had no effect. Conclusions: GPC-1 protein was expressed by most prostate cancer cell lines, including enhanced expression by enzalutamide resistant cells. Preliminary in vitro ADCC assay results revealed the potential utility of GPC-1 as an immunotherapeutic target in prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document